PRESENTATION

Q3 2026 — Presentation

Q3 2026PDF · 14 pages2.7 MB
Elevance Health
3Q 2026 Supplemental
Earnings Presentation
October 21, 2026

-- 1 of 14 --

2
Key Highlights
1 3Q 2026
Results
Results exceeded our outlook, driven by favorable benefit expense performance and strong operating execution
• Adjusted diluted EPS 1 of $6.99 reflects operating outperformance of ~$0.50 and a net non -operating benefit of ~$1.85
• Operating revenue of $50.4B increased 0.7% due to higher premium yields, CarelonRx product revenue, and service fees,
partially offset by lower health plan membership
• Benefit expense ratio of 90.6% improved 70 basis points from the prior year, as Medicaid, Medicare Advantage, and
Individual ACA delivered results favorable to our outlook
• Adjusted operating expense ratio of 11.3% increased 90 basis points from the prior year, principally due to targeted
investments in capabilities that drive our long -term performance
2 2026 Outlook
& 2027 Growth
Raising our 2026 earnings baseline 2 to at least $26.75 from at least $26.00 based on stronger operating performance
• Raising 2026 adjusted diluted EPS guidance to at least $29.00, reflecting our 3Q outperformance, an improved outlook for
our Individual ACA business, and non -operating items
• Raising 2026 operating cash flow guidance to at least $6.5 billion
Confident in delivering at least 12% adjusted diluted EPS growth in 2027, off our revised earnings baseline of at least $26.7 52
• Outlook supported by Health Benefits margin improvement, broader adoption Carelon’s value -based solutions, greater
operating efficiency, and disciplined capital deployment
3 Strategic
Focus Areas
Executing on targeted investments to strengthen medical cost management, member experience, Carelon’s value -based
capabilities, and our long -term earnings growth
Deepening adoption of Carelon’s integrated, value -based solutions across our health plans and external clients
Scaling data and analytics capabilities to identify emerging cost drivers earlier, enable targeted interventions, achieve better
health outcomes, and improve operating efficiency
1. See “GAAP Reconciliation” on slides 12 and 13 herein.
2. FY 2026 earnings baseline excludes non -recurring net investment income and other non -operating items, as well as targeted one -time investments.

-- 2 of 14 --

33
Scaling Capabilities to Drive Measurable Results
Medical Cost
Management Member
Engagement Carelon Provider
Connectivity
Our connected model builds a durable advantage: better health outcomes, lower costs, and stronger operating performance
Identify and Address
Emerging Cost Drivers Deliver a More Personal
Member Experience
Expand Integrated Care
Solutions through Carelon Improving Provider
Efficiency
1. Represents anticipated savings identified in 2026 through our Elevate insights platform for medical cost management.
2. Reflects reduction in avoidable inpatient admissions through the Cancer Care Engagement program in the Commercial market.
SAVINGS OPPORTUNITIES IDENTIFIED STRONGER MEMBER OUTCOMES EXPANDING REACH AND VALUE REDUCING ADMINISTRATIVE FRICTION
>$300M
in anticipated savings
identified year to date 1
15% reduction
in avoidable admissions for
oncology program members 2
>400 bps increase
year to date in percentage of
health plan benefit expense
managed by Carelon 3
>60% reduction
in documentation requests for
health systems on HealthOS
$
Driving better outcomes,
lower costs, and more
consistent performance
Lower
healthcare
costs
Improve
member
experience
Reduce
provider
friction
Scale
value -based
solutions
BUILDING A STRONGER AND MORE DURABLE ENTERPRISE
3. Reflects change in Carelon affiliated revenue as a percentage of Health Benefits benefit expense.

-- 3 of 14 --

44
Key Highlights
• Third quarter adjusted diluted EPS
exceeded our outlook, reflecting
favorable benefit expense performance
and disciplined execution
• Adjusted EPS of $6.99 reflected stronger
operating performance across Medicaid,
Medicare Advantage, and Individual ACA
of ~$0.50 versus our outlook, as well as a
non -operating benefit of ~$1.85
• Operating revenue growth was driven by
higher premium yields, CarelonRx
product revenue, and service fees,
partially offset by lower Government and
Employer Group risk -based membership
• Benefit expense ratio of 90.6% improved
70 basis points compared to the prior
year, driven by better performance in
Medicare Advantage and Individual ACA
• Operating cash flow of $1.3 billion
increased year over year, primarily due
to favorable working capital dynamics
3Q 2026 Results
Elevance Health 3Q 2026 3Q 2025 Change
Operating Revenue 1 $50.4B $50.1B 0.7%
Benefit Expense Ratio 90.6% 91.3% (70) bps
Adjusted Operating Expense Ratio 2 11.3% 10.4% 90 bps
Adjusted Operating Gain 1,2 $1.3B $1.3B (0.5%)
Adjusted Operating Margin 1,2 2.7% 2.7% 0 bps
Net Investment Income $1.0B $0.6B 65.9%
Adjusted Diluted EPS 2 $6.99 $6.03 15.9%
Operating Cash Flow $1.3B $1.1B $0.1B
1. See “Non -GAAP Measures and Basis of Presentation” on slide 11 herein.
2. See “GAAP Reconciliation” on slides 12 and 13 herein.

-- 4 of 14 --

55
Key Highlights
• Our Health Benefits segment performed
better than expected, driven by a
favorable benefit expense ratio, while
investing to drive future growth
• Operating revenue grew 2.6% year over
year, driven by higher premium yields and
service fees, partially offset by lower
Medicare Advantage, Medicaid, and
Employer Group risk -based membership
• Operating margin of 1.0% declined
compared to the prior year, reflecting our
targeted investments, partially offset by
an improved benefit expense ratio
• Membership of 44.9M declined from the
prior year, reflecting lower enrollment in
our Medicaid, Medicare Advantage, and
Employer Group risk -based businesses,
partially offset by growth in Commercial
fee -based membership
Health Benefits 3Q 2026 3Q 2025 Change
Operating Revenue 1 $43.4B $42.2B 2.6%
Operating Gain 1,2 $0.4B $0.6B (27.5%)
Operating Margin 1,2 1.0% 1.4% (40) bps
Membership 44.9M 45.4M (1.1%)
1. See “Non -GAAP Measures and Basis of Presentation” on slide 11 herein.
2. See “Reportable Segment Highlight & Health Benefits Revenue Details” on slide 14 herein.
Health Benefits
3Q 2026 Results

-- 5 of 14 --

66
Key Highlights
• Carelon delivered strong third quarter
results, underscoring its expanding role in
improving affordability and driving
sustainable earnings growth
• CarelonRx operating revenue reflected
higher pharmacy spending, partially offset
by lower health plan membership;
operating margin reflected specialty
pharmacy strength and reduced operating
expense
• Carelon Services operating revenue
growth was driven by our continued
expansion of risk -based solutions;
operating margin reflects improved
performance across these programs
3Q 2026 Results
Carelon 3Q 2026 3Q 2025 Change
Operating Revenue 1 $19.3B $18.3B 5.4%
Operating Gain 1,2 $0.9B $0.8B 17.2%
Operating Margin 1,2 4.7% 4.2% 50 bps
Adjusted Scripts 82.6M 85.0M (2.8%)
Consumers Served 91.0M 97.6M (6.8%)
1. See “Non -GAAP Measures and Basis of Presentation” on slide 11 herein.
2. See “Reportable Segment Highlight & Health Benefits Revenue Details” on slide 14 herein.
Health Services

-- 6 of 14 --

77
Flywheel Supports Our Long -Term Growth Algorithm
Health Benefits
Optimize
the Core
Invest in
Growth
Accelerate
Performance
Targeting at least 12% average annual growth in
Adjusted Diluted Earnings Per Share
Approximately 45M medical members
balanced across Commercial, Medicaid,
Medicare, and the Federal Employee
Program, leveraging the assets and
capabilities of Carelon to accelerate
growth
As an integrated portfolio of whole
health solutions serving approximately
91M consumers, Carelon connects care
across physical, behavioral, social,
home health, and pharmacy needs to
bend the cost curve, enhance consumer
experiences, and deliver whole health,
affordably
Health Services

-- 7 of 14 --

88
Adjusted Operating Gain – High Single Digit to Low Double Digit CAGR 1
Long -Term Growth Algorithm
Revenue Growth
High Single Digit CAGR 1
Adjusted Operating Margin
Expanding to 5.0% – 6.0%
Capital Deployment
Approximately 4% Contribution to
Adjusted Diluted EPS CAGR 1
Health Benefits
Mid to High Single Digit CAGR
Driven by targeted membership growth, strategic
geographic and product expansion, and growth in
specialized populations
Carelon Services
High Teens to Low Twenties CAGR
Driven by risk -based revenue growth and M&A
CarelonRx
Low Double Digit CAGR
Driven by new client relationships and scaling of
specialty pharmacy capabilities
Strengthen operational
discipline to accelerate margin
normalization
Advance value -based care
models to improve outcomes
and reduce costs
Integrate technology to simplify
the experience for members and
care providers
Share Repurchases
Organic Reinvestment
Programmatic M&A targeting
integrated solutions that
strengthen health plan
competitiveness
+ +
1. CAGR = Compound Annual Growth Rate Target.
Targeting at least 12% average annual growth in Adjusted Diluted EPS

-- 8 of 14 --

99
Committed to Strong Growth Over the Long -Term
M&A/ Organic
Reinvestment
50%
Share
Repurchase
30%
Dividends
20%
3.8%
5.0% – 6.0%
2025 Target
$198B
High Single
Digit CAGR 1
2025 Target
Elevance Health
4.8%
Mid Single
Digit
2025 Target
$72B
Mid Teens
CAGR 1
2025 Target
Carelon 2
2.5%
Mid Single
Digit
2025 Target
$167B
Mid to High
Single Digit
CAGR 1
2025 Target
Health Benefits
Capital
Allocation
Targeting at least 12% average annual
growth in Adjusted Diluted EPS
Adjusted 3
Operating
Margin
Revenue
(in billions)
1. CAGR = Compound Annual Growth Rate Target.
2. The CAGR target for revenue and the operating margin target for Carelon includes: ( i) a low double digit revenue CAGR and mid single digit percentage operating margin for
CarelonRx, and (ii) a high teens to low twenties revenue CAGR and mid to high single digit percentage operating margin for Ca rel on Services.
3. See “GAAP Reconciliation” on slides 12 and 13 herein.

-- 9 of 14 --

10
Forward -Looking Statements
This document contains certain forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward -looking statements reflect our views
about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believ e,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,”
“project,” “forecast,” “plan,” “potential,” “predict” and similar expressions are intended to identify forward -looking statement s. These statements include, but are not limited to:
financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and
services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many o f which are difficult to predict and generally beyond
our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the fo rwa rd -looking statements. You are cautioned not to place
undue reliance on these forward -looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other
disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect
our business. Except to the extent required by law, we do not update or revise any forward -looking statements to reflect events or circumstances occurring after the date hereof.
These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enro llm ent; our ability to secure and implement sufficient
premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catas trophes; the impact of new or changes in existing
federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmac y services and other diversified products and services,
or their enforcement or application; the impact of cyber -attacks or other privacy or data security incidents or our failure to c omply with any privacy, data or security laws or
regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and moderniz e o ur information systems, or failure of our information
systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availab ility and integrity of our data; changes in economic and
market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pre ssu res and our ability to adapt to changes in the industry
and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, i ncl uding those related to non -compliance with
the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Se rvices Star Ratings and other quality scores
and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mi x; costs and other liabilities associated with litigation,
government investigations, audits or reviews; our ability to contract with providers on cost -effective and competitive terms; ri sks associated with providing healthcare, pharmacy
and other diversified products and services, including medical malpractice or professional liability claims and non -compliance b y any party with the pharmacy services agreement
between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity or sentiment related to the health benefits industry in general or us i n particular; risks associated
with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and
other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required mi nim um levels of capital; our ability to repurchase shares
of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other conside rat ions; the potential negative effect from our
substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact o ur access to or further increase the cost of financing; a
downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shie ld Association; intense competition to attract and retain
employees; risks associated with our international operations; and various laws and provisions in our governing documents tha t may prevent or discourage takeovers and business
combinations.

-- 10 of 14 --

11
Non -GAAP Measures and Basis of Presentation
This document references non -GAAP measures, including “Adjusted Diluted EPS,” “Adjusted Operating Expense Ratio,” “Adjusted Oper ating Gain,” “Adjusted Operating Margin,”
“Adjusted Shareholders’ Net Income,” and “Adjusted Operating Expense”. These non -GAAP measures are intended to aid investors wh en comparing Elevance Health’s financial
results among periods and are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliati ons of these non -GAAP measures to the most
directly comparable measures calculated in accordance with GAAP are available on slides 12 -13 of this document.
In addition to these non -GAAP measures, references are made to the measures “Operating Revenue,” “Operating Gain/Loss,” and “Ope rating Margin”. Operating revenue and
operating gain/loss are the key measures used by management to evaluate performance in each of its reportable segments, alloc ate resources, set incentive compensation
targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benef it expense, cost of products sold and operating
expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets and gains/losses on
extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the res ponsibility of operating segment
management. Each of these measures is provided to further aid investors in understanding and analyzing Elevance Health’s oper ati ng and financial results. A reconciliation of
reportable segments operating gain to income before income tax expense is available on slide 12 of this document. Prior amoun ts may be grouped differently to conform to the
current presentation.

-- 11 of 14 --

12	12
GAAP Reconciliation — Shareholders’ Net Income and Shareholders’
Earnings Per Diluted Share Three Months Ended Sep 30 Nine Months Ended Sep 30
(In millions, except per share data) 2026 2025 Change 2026 2025 Change
Shareholders' net income $1,365 $1,189 14.8% $4,592 $5,115 (10.2%)
Add / (Subtract):
Amortization of other intangible assets 106 162 328 464
Net losses on financial instruments 48 1 182 596
Transaction and integration related costs 1 42 49 133 182
Business optimization program charges 1 18 (4) 147 (4)
Litigation and settlement expenses 1 8 4 26 19
Accrual related to CMS notice 1,2 — — 935 —
Tax impact of non -GAAP adjustments (67) (52) (427) (307)
Net adjustment items 155 160 1,324 950
Adjusted shareholders' net income $1,520 $1,349 12.7% $5,916 $6,065 (2.5%)
Shareholders’ earnings per diluted share $6.27 $5.32 17.9% $21.01 $22.67 (7.3%)
Add / (Subtract):
Amortization of other intangible assets 0.49 0.72 1.50 2.06
Net losses on financial instruments 0.22 — 0.83 2.64
Transaction and integration related costs 1 0.19 0.22 0.61 0.81
Business optimization program charges 1 0.08 (0.02) 0.67 (0.02)
Litigation and settlement expenses 1 0.04 0.02 0.12 0.08
Accrual related to CMS notice 1,2 — — 4.28 —
Tax impact of non -GAAP adjustments (0.31) (0.23) (1.95) (1.36)
Net adjustment items 0.72 0.71 6.05 4.21
Adjusted shareholders’ earnings per diluted share 3 $6.99 $6.03 15.9% $27.06 $26.88 0.7%
Three Months Ended Sep 30 Nine Months Ended Sep 30
(In millions) 2026 2025 Change 2026 2025 Change
Income before income tax expense $1,794 $1,406 27.6% $6,035 $6,495 (7.1%)
Net investment income (1,037) (625) (2,506) (1,701)
Net losses on financial instruments 48 1 182 596
Interest expense 358 351 1,079 1,036
Amortization of other intangible assets 106 162 328 464
Reportable segments operating gain $1,269 $1,295 (2.0%) $5,118 $6,890 (25.7%)
1. Adjustment item resides in the Corporate & Other reportable segment
2. Adjustment item represents the Company's current best estimate of the identified potential exposure for certain historical Me dic are Advantage risk adjustment data related to the CMS notice to the Company dated February 27, 2026.
3. Totals may not foot due to rounding.

-- 12 of 14 --

13	13
GAAP Reconciliation — Operating Gain, Operating Expense Ratio, and
2026 Outlook
(In millions)
Operating expense $5,752 $5,272 9.1% $17,629 $15,569 13.2%
Add / (Subtract):
Transaction and integration related costs 1 (42) (49) (133) (182)
Business optimization program charges 1 (18) 4 (147) 4
Litigation and settlement expenses 1 (8) (4) (26) (19)
Accrual related to CMS notice 1,2 — — (935) —
Net adjustment Items (68) (49) (1,241) (197)
Adjusted operating expense $5,684 $5,223 8.8% $16,388 $15,372 6.6%
Operating revenue $50,440 $50,087 0.7% $149,760 $148,273 1.0%
Operating expense ratio 11.4% 10.5% 90 bp 11.8% 10.5% 130 bp
Adjusted operating expense ratio 11.3% 10.4% 90 bp 10.9% 10.4% 50 bp
Three Months Ended Sep 30 Nine Months Ended Sep 30
(In millions) 2026 2025 Change 2026 2025 Change
Reportable segments operating gain $1,269 $1,295 (2.0%) $5,118 $6,890 (25.7%)
Add / (Subtract):
Transaction and integration related costs 1 42 49 133 182
Business optimization program charges 1 18 (4) 147 (4)
Litigation and settlement expenses 1 8 4 26 19
Accrual related to CMS notice 1,2 — — 935 —
Net adjustment Items 68 49 1,241 197
Reportable segments adjusted operating gain $1,337 $1,344 (0.5%) $6,359 $7,087 (10.3%)
Full Year 2026 Outlook
Shareholders’ earnings per diluted share At least $22.00
Add / (Subtract):
Accrual related to CMS notice 1,2 $4.28
Amortization of other intangible assets 3 $2.02
Net losses on financial instruments 3 $1.16
Transaction and integration related costs 1,3 $0.91
Business optimization program charges 1 $0.67
Litigation and settlement expenses 1,3 $0.16
Tax impact of non -GAAP adjustments 3 Approximately ($2.20)
Net adjustment items $7.00
Adjusted shareholders’ earnings per diluted share At least $29.00
1. Adjustment item resides in the Corporate & Other reportable segment.
2. Adjustment item represents the Company's current best estimate of the identified potential exposure for certain historical Me dic are Advantage risk adjustment data related to the CMS notice to the Company dated February 27, 2026.
3. Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount.
Operating revenue $50,440 $50,087 0.7% $149,760 $148,273 1.0%
Operating margin 2.5% 2.6% (10) bp 3.4% 4.6% (120) bp
Adjusted operating margin 2.7% 2.7% 0 bp 4.2% 4.8% (60) bp

-- 13 of 14 --

14	14
Reportable Segment & Health Benefits Revenue Details
Three Months Ended Sep 30 Nine Months Ended Sep 30
(In millions, Unaudited) 2026 2025 Change 2026 2025 Change
Operating Revenue
Health Benefits $43,357 $42,246 2.6% $128,567 $125,259 2.6%
CarelonRx 11,599 10,997 5.5% 33,449 31,756 5.3%
Carelon Services 7,708 7,324 5.2% 23,048 21,301 8.2%
Corporate & Other 6 149 (96.0%) 16 546 (97.1%)
Eliminations (12,230) (10,629) NM6 (35,320) (30,589) NM6
Total Operating Revenue 1 $50,440 $50,087 0.7% $149,760 $148,273 1.0%
Operating Gain (Loss)
Health Benefits $436 $601 (27.5%) $3,489 $4,378 (20.3%)
CarelonRx 616 556 10.8% 1,780 1,694 5.1%
Carelon Services 292 219 33.3% 1,128 1,110 1.6%
Corporate & Other 2,3 (75) (81) NM6 (1,279) (292) NM6
Total Operating Gain 1,4 $1,269 $1,295 (2.0%) $5,118 $6,890 (25.7%)
Operating Margin
Health Benefits 1.0% 1.4% (40) bp 2.7% 3.5% (80) bp
CarelonRx 5.3% 5.1% 20 bp 5.3% 5.3% 0 bp
Carelon Services 3.8% 3.0% 80 bp 4.9% 5.2% (30) bp
Total Operating Margin 1 2.5% 2.6% (10) bp 3.4% 4.6% (120) bp
1. See “Basis of Presentation” on slide 11 herein.
2. Operating Gain for the three and nine months ended September 30, 2026 included $42 and $133 million, respectively, of transac tion and integration related costs, $18 and $147 million, respectively, of business optimization charges, and $8 and $26 million , respectively, of litigation and settlement expenses. Operating
Gain for the nine months ended September 30, 2026 also included $935 million for the Company's current best estimate of the i den tified potential exposure for certain historical Medicare Advantage risk adjustment data related to the CMS notice to the Com pan y dated February 27, 2026. All adjustments for the three
and nine month periods reside in the Corporate & Other reportable segment.
3. Operating Gain for the three and nine months ended September 30, 2025, included $49 and $182 million, respectively, of transa ction and integration related costs, ($4) and ($4) million, respectively, of business optimization charges, and $4 and $19 milli on, respectively, of litigation and settlement expenses. All
adjustments for the three and nine month periods reside in the Corporate & Other reportable segment.
4. Operating Gain for the three and nine months ended September 30, 2026, and September 30, 2025, include items excluded from ad justed shareholders' net income. See "GAAP Reconciliation" on pages 12 and 13 herein.
5. The Individual business, including ACA products, is reported as part of Commercial Operating Revenue.
6. "NM" = calculation not meaningful.
Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk -based, Employer Grou p fee -based, BlueCard®, Medicare, Medicaid, and Federal Employee Program
businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the qu ant itative thresholds for an operating division as well as corporate expenses not
allocated to our other reportable segments).
Three Months Ended Sep 30 Nine Months Ended Sep 30
(In millions, Unaudited) 2026 2025 Change 2026 2025 Change
Health Benefits Operating Revenue
Commercial $13,343 $12,849 3.8% $40,142 $37,654 6.6%
Individual 5 2,514 2,358 6.6% 7,774 7,047 10.3%
Medicare 11,229 11,138 0.8% 33,182 33,990 (2.4%)
Medicaid 14,979 14,166 5.7% 43,703 42,120 3.8%
Federal Employee Program 3,806 4,093 (7.0%) 11,540 11,495 0.4%
Total Health Benefits Operating Revenue 1 $43,357 $42,246 2.6% $128,567 $125,259 2.6%

-- 14 of 14 --